Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cholecalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholecalciferol SCHEMBL579140 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL10034116 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL7151131 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL15694 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL3127 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL23878716 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL8030832 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL21264875 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL20511118 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL267918 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107523546-A | A kind of NK cells of high efficiency stable expression antibody and application thereof | 上海细胞治疗研究院 | 2017-12-29 | — | — | CN | claimed |
| CN-107523547-A | A kind of CAR T cells of high efficiency stable expression inhibiting antibody and application thereof | 上海细胞治疗研究院 | 2017-12-29 | — | — | CN | claimed |
| CN-107523548-A | A kind of T cell of high efficiency stable expression antibody and application thereof | 上海细胞治疗研究院 | 2017-12-29 | — | — | CN | claimed |
| CN-107523545-A | A kind of lethal cell of high efficiency stable expression antibody and application thereof | 上海细胞治疗研究院 | 2017-12-29 | — | — | CN | claimed |
| CN-107523549-A | CAR-T cell for efficiently and stably expressing activated antibody and application thereof | 上海细胞治疗研究院 | 2017-12-29 | — | — | CN | claimed |
| CN-114729004-B | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12042515-B2 | Killer cell capable of efficiently and stably expressing antibody, and uses thereof | SHANGHAI CELL THERAPY RESEARCH INSTITUTE (CN) | 2024-07-23 | — | — | US | disclosed |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118108833-A | TCR constant region introduced with exogenous disulfide bond, and product and application thereof | 缇纱(合肥)生物技术有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-114729361-B | Promoter with high activity in activated T cells | 上海细胞治疗集团股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-109971725-B | Antibody-modified chimeric antigen receptor-modified T cells and uses thereof | 上海细胞治疗研究院 | 2024-02-02 | — | — | CN | disclosed |
| US-8003400-B2 | Measurement of vitamin D | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110097733-A1 | PROCESS FOR THE PRODUCTION OF A HYBRIDOMA AND ANTIBODY OBTAINED THEREFROM, ABLE TO RECOGNIZE MORE THAN ONE VITAMIN D METABOLITE | DIASOURCE IMMUNOASSAYS S.A. (BE) | 2011-04-28 | — | — | US | disclosed |
| US-20100285603-A1 | MEASUREMENT OF VITAMIN D | ROCHE DIAGNOSTICS GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| CN-101479389-A | Hepatitis C virus infection biomarkers | VERTEX PHARMA (US) | 2009-07-08 | — | — | CN | disclosed |
| US-20090093445-A1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20080317764-A1 | ANTIBODIES AGAINST 25-HYDROXYVITAMIN D | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2008-12-25 | — | — | US | disclosed |
| CN-101188942-A | Adult pancreatic derived stromal cells | LIFESCAN INC (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-1959401-A | Multimode ionization source and method for screening molecules | AGILENT TECHNOLOGIES INC (US) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097733-A1 | PROCESS FOR THE PRODUCTION OF A HYBRIDOMA AND ANTIBODY OBTAINED THEREFROM, ABLE TO RECOGNIZE MORE THAN ONE VITAMIN D METABOLITE | CYP2R1, CYP24A1, CYP27B1 | VDR 4/4885MEN1 1664/4885KMT2A 3834/4885 |
| US-20090093445-A1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | GC, VDR, CYP24A1 | VDR 2/4885MEN1 959/4885KMT2A 4799/4885 |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | MTREX, HAVCR2, TSG101 | VDR 643/4885MEN1 2915/4885KMT2A 4172/4885 |
| US-20080317764-A1 | ANTIBODIES AGAINST 25-HYDROXYVITAMIN D | CYP2R1, CYP24A1, VDR | VDR 3/4885MEN1 1995/4885KMT2A 4047/4885 |
| US-12042515-B2 | Killer cell capable of efficiently and stably expressing antibody, and uses thereof | FCGR1A, FCGR2A, FCGR3B | VDR 948/4885MEN1 3125/4885KMT2A 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.